Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 12, 2026 |
| Emmaus Life Sciences, Inc.MYND · Entity 205 | Director | October 08, 2018 | November 20, 2018 |
| Telemynd, Inc.NONE · Entity 155932 | Director | June 25, 2019 | July 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
Emmaus Life Sciences, Inc.
Report date October 08, 2018 · Filed November 20, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2018-10-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-10-08 · Grant · Acquired 144,000 · Balance 144,000 F1: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ. Row 2 · 2018-10-08 · Disposition to issuer · Disposed 144,000 · Balance 0 F1: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ.
Telemynd, Inc.
Report date June 25, 2019 · Filed July 05, 2019
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 12, 2026 19:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-26-002978 · tm262917d4_4seq1.xml · derivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 19:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | OtherStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001104659-24-070518 · tm2416928-5_4seq1.xml · derivative · entry 2 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2034-06-10 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 19:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001104659-24-070518 · tm2416928-5_4seq1.xml · derivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-06-10 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 16:56 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | OtherStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001104659-23-075863 · tm2319786-3_4seq1.xml · derivative · entry 2 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2033-06-26 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 16:56 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001104659-23-075863 · tm2319786-3_4seq1.xml · derivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-26 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| May 19, 2022 Filed May 23, 2022 18:48 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | OtherStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001104659-22-063971 · tm2216669-2_4seq.xml · derivative · entry 2 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2032-05-19 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| May 19, 2022 Filed May 23, 2022 18:48 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001104659-22-063971 · tm2216669-2_4seq.xml · derivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-05-19 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:36 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | OtherStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001104659-21-081588 · tm2119762-2_4seq1.xml · derivative · entry 2 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,500 shares Expires 2031-06-11 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:36 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001104659-21-081588 · tm2119762-2_4seq1.xml · derivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2031-06-11 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 16:17 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | OtherStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001104659-20-065871 · a4.xml · derivative · entry 2 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-05-21 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 16:17 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001104659-20-065871 · a4.xml · derivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-21 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 23, 2019 Filed Jun 19, 2019 21:07 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | OtherStock Option (Right to Buy) · Derivative | 4,700 | $0.00 Strike: $10.04 | $0.00 |
DisclosureSEC source: 0001104659-19-036496 · a4.xml · derivative · entry 2 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,700 shares Expires 2029-05-23 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option will vest in full and become exercisable on the first anniversary of the grant date. Read SEC document |
| May 23, 2019 Filed Jun 19, 2019 21:07 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 4,700 | $0.00 Strike: $10.04 | $0.00 |
DisclosureSEC source: 0001104659-19-036496 · a4.xml · derivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 Underlying: Common Stock · 4,700 shares Expires 2029-05-23 F1 · kind: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein. F2 · derivative.exercise_date: The option will vest in full and become exercisable on the first anniversary of the grant date. Read SEC document |
| March 07, 2019 Filed Mar 18, 2019 17:38 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Disposition to issuerStock Options (Right to Buy) · Derivative | 10,000 | $7.91 Strike: $7.91 | $79,100.00 |
DisclosureSEC source: 0001104659-19-015669 · a4.xml · derivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: The shares underlying this stock option vest as follows: one-third on each of 3/7/2020, 3/7/2021 and 3/7/2022, subject to the Reporting Person's continuous service to the Issuer through such dates. F2 · derivative.underlying_shares: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of the Issuer with the permission of RSJ. Read SEC document |
| October 08, 2018 Filed Oct 11, 2018 01:26 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantCOMMON STOCK | 144,000 | $1.38 | $198,720.00 |
DisclosureSEC source: 0001615774-18-010703 · s113238_form4.xml · nonDerivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 F1 · shares: On October 8, 2018, the Reporting Person was granted 144,000 restricted shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person has assigned all benefits resulting from the grant of restricted common stock and options to RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus pod fond, RSJ Investments SICAV a.s. F1 · balance_after: On October 8, 2018, the Reporting Person was granted 144,000 restricted shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person has assigned all benefits resulting from the grant of restricted common stock and options to RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus pod fond, RSJ Investments SICAV a.s. Read SEC document |
| October 08, 2018 Filed Nov 20, 2018 22:56 UTC Amendment | Emmaus Life Sciences, Inc. MYND · Entity 205 | Disposition to issuerCOMMON STOCK | 144,000 | $1.38 | $198,720.00 |
DisclosureSEC source: 0001615774-18-013077 · s114147_form4.xml · nonDerivative · entry 2 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ. F1 · shares: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ. F1 · acquired: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ. Read SEC document |
| October 08, 2018 Filed Nov 20, 2018 22:56 UTC Amendment | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantCOMMON STOCK | 144,000 | $1.38 | $198,720.00 |
DisclosureSEC source: 0001615774-18-013077 · s114147_form4.xml · nonDerivative · entry 1 Votruba Michal · CIK 0001653967 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 F1 · kind: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ. F1 · shares: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ. F1 · acquired: On October 8, 2018, the Reporting Person was granted 144,000 shares of restricted common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person immediately and automatically assigned all benefits resulting from the October 8, 2018 grant of restricted common stock to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of MYnd Analytics, Inc. at the request of RSJ. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.